Overcoming therapy resistance in EGFR-mutant lung cancer

被引：388

作者：

Passaro, Antonio ^{[1
]}

Janne, Pasi A. ^{[2
,3
]}

Mok, Tony ^{[4
]}

Peters, Solange ^{[5
]}

机构：

[1] IRCCS, European Inst Oncol, Div Thorac Oncol, Milan, Italy

[2] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA

[3] Harvard Med Sch, Boston, MA 02115 USA

[4] Chinese Univ Hong Kong, Dept Clin Oncol, State Key Lab Translat Oncol, Hong Kong, Peoples R China

[5] Ctr Hosp Univ Vaudois CHUV, Dept Oncol, Lausanne, Switzerland

来源：

NATURE CANCER | 2021年 / 2卷 / 04期

关键词：

GROWTH-FACTOR RECEPTOR; CIRCULATING TUMOR DNA; CISPLATIN PLUS GEMCITABINE; PHASE-III TRIAL; CELL-FREE DNA; OPEN-LABEL; BRAIN METASTASES; DRUG-RESISTANCE; T790M MUTATION; 1ST-LINE TREATMENT;

D O I：

10.1038/s43018-021-00195-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR)-activating mutations. Despite prolonged disease control and high tumor response rates, all patients eventually progress on EGFR TKI treatment. Here, we review the mechanisms of acquired EGFR TKI resistance, the methods for monitoring its appearance, as well as current and future efforts to define treatment strategies to overcome resistance. Passaro and colleagues discuss recent advances in treating EGFR-mutant lung cancer, including methods for detecting disease and tracking therapy response, developments in understanding of resistance mechanisms and ongoing clinical trials to circumvent therapeutic resistance to EGFR targeting.

引用

页码：377 / 391

页数：15

共 189 条

[1] Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer [J].

Aggarwal, Charu ;

Thompson, Jeffrey C. ;

Black, Taylor A. ;

Katz, Sharyn I. ;

Fan, Ryan ;

Yee, Stephanie S. ;

Chien, Austin L. ;

Evans, Tracey L. ;

Bauml, Joshua M. ;

Alley, Evan W. ;

Ciunci, Christine A. ;

Berman, Abigail T. ;

Cohen, Roger B. ;

Lieberman, David B. ;

Majmundar, Krishna S. ;

Savitch, Samantha L. ;

Morrissette, Jennifer J. D. ;

Hwang, Wei-Ting ;

Elenitoba-Johnson, Kojo S. J. ;

Langer, Corey J. ;

Carpenter, Erica L. .

JAMA ONCOLOGY, 2019, 5 (02) :173-180

[2] Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study [J].

Ahn, Myung-Ju ;

Han, Ji-Youn ;

Lee, Ki Hyeong ;

Kim, Sang-We ;

Kim, Dong-Wan ;

Lee, Yun-Gyoo ;

Cho, Eun Kyung ;

Kim, Joo-Hang ;

Lee, Gyeong-Won ;

Lee, Jong-Seok ;

Min, Young Joo ;

Kim, Jin-Soo ;

Lee, Sung Sook ;

Kim, Hye Ryun ;

Hong, Min Hee ;

Ahn, Jin Seok ;

Sun, Jong-Mu ;

Kim, Heung Tae ;

Lee, Dae Ho ;

Kim, Sohee ;

Cho, Byoung Chul .

LANCET ONCOLOGY, 2019, 20 (12) :1681-1690

[3] MET amplification and activating mutation analysis in solid tumors using comprehensive NGS panel. [J].

Ai, Xinghao ;

Yuan, Mingming ;

Zhao, Jun ;

Miao, Liyun ;

Lin, Gen ;

Du, Xueming ;

Wu, Jun ;

Zhang, Longbo ;

Cheng, Xiangyang ;

Xu, Chunwei ;

Wang, Wen-xian ;

Chen, Rongrong ;

Xia, Xuefeng .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

[4] Signatures of mutational processes in human cancer [J].

Alexandrov, Ludmil B. ;

Nik-Zainal, Serena ;

Wedge, David C. ;

Aparicio, Samuel A. J. R. ;

Behjati, Sam ;

Biankin, Andrew V. ;

Bignell, Graham R. ;

Bolli, Niccolo ;

Borg, Ake ;

Borresen-Dale, Anne-Lise ;

Boyault, Sandrine ;

Burkhardt, Birgit ;

Butler, Adam P. ;

Caldas, Carlos ;

Davies, Helen R. ;

Desmedt, Christine ;

Eils, Roland ;

Eyfjord, Jorunn Erla ;

Foekens, John A. ;

Greaves, Mel ;

Hosoda, Fumie ;

Hutter, Barbara ;

Ilicic, Tomislav ;

Imbeaud, Sandrine ;

Imielinsk, Marcin ;

Jaeger, Natalie ;

Jones, David T. W. ;

Jones, David ;

Knappskog, Stian ;

Kool, Marcel ;

Lakhani, Sunil R. ;

Lopez-Otin, Carlos ;

Martin, Sancha ;

Munshi, Nikhil C. ;

Nakamura, Hiromi ;

Northcott, Paul A. ;

Pajic, Marina ;

Papaemmanuil, Elli ;

Paradiso, Angelo ;

Pearson, John V. ;

Puente, Xose S. ;

Raine, Keiran ;

Ramakrishna, Manasa ;

Richardson, Andrea L. ;

Richter, Julia ;

Rosenstiel, Philip ;

Schlesner, Matthias ;

Schumacher, Ton N. ;

Span, Paul N. ;

Teague, Jon W. .

NATURE, 2013, 500 (7463) :415-+

[5]

Apostolou P, 2018, ANN ONCOL, V29

[6] CNS metastasis: An old problem in a new guise [J].

Aragon-Ching, Jeanny B. ;

Zujewski, Jo Anne .

CLINICAL CANCER RESEARCH, 2007, 13 (06) :1644-1647

[7] Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases [J].

Arbour, Kathryn C. ;

Kris, Mark G. ;

Riely, Gregory J. ;

Ni, Ai ;

Beal, Kathryn ;

Daras, Mariza ;

Hayes, Sara A. ;

Young, Robert J. ;

Rodriguez, Christopher R. ;

Ahn, Linda ;

Pao, William ;

Yu, Helena A. .

CANCER, 2018, 124 (01) :105-109

[8] Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer [J].

Arulananda, Surein ;

Do, Hongdo ;

Musafer, Ashan ;

Mitchell, Paul ;

Dobrovic, Alexander ;

John, Thomas .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) :1728-1732

[9] Therapeutic approaches for T790M mutation positive non-small-cell lung cancer [J].

Attili, Ilaria ;

Karachaliou, Niki ;

Conte, PierFranco ;

Bonanno, Laura ;

Rosell, Rafael .

EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (10) :1021-1030

[10] Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity [J].

Ballard, Peter ;

Yates, James W. T. ;

Yang, Zhenfan ;

Kim, Dong-Wan ;

Yang, James Chih-Hsin ;

Cantarini, Mireille ;

Pickup, Kathryn ;

Jordan, Angela ;

Hickey, Mike ;

Grist, Matthew ;

Box, Matthew ;

Johnstrom, Peter ;

Varnas, Katarina ;

Malmquist, Jonas ;

Thress, Kenneth S. ;

Janne, Pasi A. ;

Cross, Darren .

CLINICAL CANCER RESEARCH, 2016, 22 (20) :5130-5140

← 1 2 3 4 5 6 7 8 9 10 →